TABLE 1.

In vitro activity of tigecycline against 392 multiple-drug-resistant strains

Organism (no. of isolates)	MIC50 (μg/ml)	MIC90 (μg/ml)	% Susceptiblea	No. of isolates with MIC (μg/ml) of:
				≤0.03	0.06	0.12	0.25	0.5	1	2	4	≥8
K. pneumoniae (98)	0.5	2	96.9	0	1	4	26	37	11	16	3	0
K. pneumoniae, ESBL positive (27)	1	2	92.6	0	0	0	5	8	4	8	2	0
K. pneumoniae, MBL positive (26)	0.5	2	100	0	0	3	9	9	2	3	0	0
K. pneumoniae, ESBL and MBL positive (28)	0.5	2	100	0	0	1	7	13	2	5	0	0
K. pneumoniae, colistin resistant (15)	0.5	0.5	100	0	1	1	3	9	0	1	0	0
K. pneumoniae, minocycline resistant (28)	2	4	89.3	0	0	0	0	2	8	15	3	0
E. coli (43)	0.12	0.5	100	0	8	18	11	5	1	0	0	0
E. coli, ESBL positive (33)	0.12	0.5	100	0	8	13	8	3	1	0	0	0
E. coli, MBL positive (6)	NAc	NA	100	0	0	3	2	1	0	0	0	0
E. coli, minocycline resistant (10)	0.12	0.5	100	0	1	4	3	1	1	0	0	0
A. baumannii (100)	0.5	1	99	0	0	1	5	46	44	3	1	0
A. baumannii, colistin resistant (3)	NA	NA	100	0	0	0	0	2	1	0	0	0
MRSA (91)	0.25	0.25	98.9	0	0	27	58	5	0	1	0	0
E. faecium, VRb (60)	0.03	0.06	100	46	12	2	0	0	0	0	0	0
E. faecium, VR, linezolid resistant (5)	NA	NA	100	2	3	0	0	0	0	0	0	0

^aTigecycline susceptibility breakpoints used were as follows: ≤2 μg/ml for Enterobacteriaceae and A. baumannii, ≤0.5 μg/ml for S. aureus, and ≤0.25 μg/ml for E. faecium.

^bVR, vancomycin resistant.

^cNA, not applicable.